Chenglong Li

US Patent:

20120053208, Mar 1, 2012

Filed:

Apr 15, 2010

Appl. No.:

13/264580

Inventors:

Chenglong Li - Dublin OH, US
Jiayuh Lin - Dublin OH, US
James R. Fuchs - Columbus OH, US

Assignee:

THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION - Columbus OH

International Classification:

A61K 31/4465
C07D 309/06
C07D 211/32
A61K 31/12
C12Q 1/48
A61P 35/00
A61P 3/10
A61P 29/00
C12Q 1/02
C12Q 1/68
C07C 49/577
A61K 31/351

US Classification:

514330, 568329, 568330, 549425, 546225, 514683, 514684, 514451, 435 29, 435 61, 435 15

Abstract:

Curcumin analogues and methods of making and using the same are disclosed.

US Patent:

20130059892, Mar 7, 2013

Filed:

Dec 22, 2010

Appl. No.:

13/518828

Inventors:

Robert Baiocchi - Dublin OH, US
Chenglong Li - Dublin OH, US
Pui Kai Li - Galloway OH, US
Fengting Yan - Columbus OH, US

Assignee:

The Ohio State University Research Foundation - Columbus

International Classification:

A61K 31/4439
C07D 401/14
A61P 35/00
C07D 401/12

US Classification:

514339, 5462767

Abstract:

Disclosed herein are compositions and methods for cancer detection and treatment. Compounds that inhibit PRMT5 are contemplated, as are pharmaceutical compositions comprising a therapeutically effective amount of at least one PRMT5 inhibitor. In some embodiments pharmaceutical compositions further comprising at least one HDAC inhibitor are contemplated. Methods of treating disorders in a mammal by inhibiting PRMT5 by administering to a mammal, a therapeutically effective amount of a PRMT5 inhibitor are also disclosed.

US Patent:

20140031291, Jan 30, 2014

Filed:

Jul 18, 2013

Appl. No.:

13/945753

Inventors:

Peter Mohler - Powell OH, US
Cynthia Carnes - Columbus OH, US
Chenglong Li - Dublin OH, US
Thomas Hund - Columbus OH, US

Assignee:

THE OHIO STATE UNIVERSITY - Columbus OH

International Classification:

C12Q 1/68

US Classification:

514 124, 435 612, 514165

Abstract:

Disclosed herein are methods for the diagnosis, detection, and treatment of cardiovascular disease and symptoms thereof in a subject. Disclosed herein are methods of diagnosing ischemic heart disease, non-ischemic heart disease, myocardial infarction, tachy-pacing induced non-ischemic heart disease, heart failure, and catecholaminergic-induced arrhythmia and symptoms thereof in a subject. Disclosed herein are methods of screening the efficacy of a pharmaceutical agent for treating cardiovascular disease and symptoms thereof in a subject. Disclosed herein are methods of identifying a subject eligible for a cardiovascular disease treatment clinical trial

US Patent:

20110212911, Sep 1, 2011

Filed:

Nov 24, 2010

Appl. No.:

12/954038

Inventors:

Chenglong Li - Dublin OH, US
Jiayuh Lin - Dublin OH, US

International Classification:

A61K 31/18
C07C 311/29
C07C 303/38
C12N 5/00
A61K 31/704
A61K 31/7068
C12Q 1/02
C12Q 1/68
A61P 35/00

US Classification:

514 34, 564 88, 514602, 435375, 514 49, 435 29, 435 614

Abstract:

The present invention provides small molecules useful to affect cancer cells, along with related methods. The present compounds, formulations, kits and methods are useful for a variety of research, diagnostic and therapeutic purposes. STAT3 inhibitors, particularly LLL12, are disclosed. The STAT3 inhibitors are useful to treat breast cancer in general and breast cancer initiating cells in particular.

US Patent:

20230103257, Mar 30, 2023

Filed:

Aug 22, 2022

Appl. No.:

17/821286

Inventors:

- Columbus OH, US
Chenglong Li - Gainesville FL, US
Michael Racke - Powell OH, US

International Classification:

A61K 31/428
A61K 31/18

Abstract:

In one aspect, the disclosure relates to prodrug compositions of a STAT inhibitor compound. In some aspects, the STAT is STAT3. Disclosed are pharmaceutical compositions comprising the prodrug inhibitors of STAT. In various aspects, the prodrug inhibitors of STAT can be used in methods of treating an inflammatory disorder, including multiple sclerosis, or a disorder of uncontrolled cellular proliferation, such as a cancer. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

US Patent:

20200339525, Oct 29, 2020

Filed:

Sep 27, 2018

Appl. No.:

16/650494

Inventors:

- Columbus OH, US
Chenglong Li - Gainesville FL, US
Michael Racke - Powell OH, US

International Classification:

C07D 275/06
A61P 29/00
A61P 25/00
C07F 9/6553
A61P 37/06

Abstract:

In one aspect, the disclosure relates to prodrug compositions of a STAT inhibitor compound. In some aspects, the STAT is STAT3. Disclosed are pharmaceutical compositions comprising the prodrug inhibitors of STAT. In various aspects, the prodrug inhibitors of STAT can be used in methods of treating an inflammatory disorder, including multiple sclerosis, or a disorder of uncontrolled cellular proliferation, such as a cancer. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

US Patent:

20190270707, Sep 5, 2019

Filed:

Jul 19, 2018

Appl. No.:

16/039365

Inventors:

- Columbus OH, US
Chenglong Li - Dublin OH, US
Hongshan Lai - Columbus OH, US
Said Sif - Dublin OH, US

International Classification:

C07D 209/82
C07D 209/86
C07D 209/88

Abstract:

The disclosure relates to PRMT5 inhibitors, including optionally substituted N-alkyl-9H-carbazole analogs, derivatives thereof, and related compounds; synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating disorders of uncontrolled cellular proliferation and benign hematologic diseases using the compounds and compositions.

US Patent:

20160052910, Feb 25, 2016

Filed:

May 4, 2015

Appl. No.:

14/703650

Inventors:

- Columbus OH, US
Chenglong Li - Dublin OH, US
Pui Kai Li - Galloway OH, US
Fengting Yan - Columbus OH, US

Assignee:

Ohio State Innovation Foundation - Columbus OH

International Classification:

C07D 401/12
A61K 45/06
A61K 31/706
A61K 31/4439
A61K 31/185

Abstract:

Disclosed herein are compositions and methods for cancer detection and treatment. Compounds that inhibit PRMT5 are contemplated, as are pharmaceutical compositions comprising a therapeutically effective amount of at least one PRMT5 inhibitor. In some embodiments pharmaceutical compositions further comprising at least one HDAC inhibitor are contemplated. Methods of treating disorders in a mammal by inhibiting PRMT5 by administering to a mammal, a therapeutically effective amount of a PRMT5 inhibitor are also disclosed.